Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
Saved in:
| Title: | Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial. |
|---|---|
| Authors: | Cao, Jun1 (AUTHOR), Teng, Yuee2 (AUTHOR), Li, Huiping3 (AUTHOR), Zhang, Lili4 (AUTHOR), Ouyang, Quchang5 (AUTHOR), Xie, Weimin6 (AUTHOR), Pan, Yueyin7 (AUTHOR), Song, Zhenchuan8 (AUTHOR), Ling, Xiaoling9 (AUTHOR), Wu, Xiaohong10 (AUTHOR), Xu, Jingwei11 (AUTHOR), Li, Li12 (AUTHOR), Ren, Liping13 (AUTHOR), Wang, Hong14 (AUTHOR), Zhou, Dongxian15 (AUTHOR), Luo, Jing16 (AUTHOR), Hu, Xichun1 (AUTHOR) xchu2009@hotmail.com |
| Source: | BMC Medicine. 8/9/2023, Vol. 21 Issue 1, p1-10. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
